Ratings Quantum-Si incorporated

Equities

QSI

US74765K1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
1.52 ^USD	-2.56%		-6.17%	-24.38%

May. 30	Quantum-Si Incorporated Announces Board Changes	CI
May. 15	Transcript : Quantum-Si incorporated - Shareholder/Analyst Call

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
QUANTUM-SI INCORPORATED	-24.38%	221M	-
MODERNA, INC.	+43.36%	58.06B	B-
IQVIA HOLDINGS INC.	-5.31%	40.53B	B
LONZA GROUP AG	+37.52%	38.99B	A
ICON PUBLIC LIMITED COMPANY	+14.75%	26.7B	B-
CELLTRION, INC.	-12.56%	26.56B	C
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.98B	B
BIO-TECHNE CORPORATION	+0.04%	12.17B	B+
UNITED THERAPEUTICS CORPORATION	+25.12%	12B	B+
MEDPACE HOLDINGS, INC.	+26.04%	11.92B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes